Catalent, Inc. Reports Second Quarter Fiscal 2021 Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/20/2026
- Wall St slips on rising bond yields; Walmart results weigh
- Walmart shares fall despite earnings beat
- Alibaba stock dips as Q2 profit misses estimates despite strong AI cloud growth
- Wolfe remains "broadly bullish on AI semis stocks", names Top Pick
- Moderna stock pulls back after massive one-day rally: analysts weigh in
- Marvell issues Google warrant tied to custom chip deal
- FOMC minutes from July 28-29th meeting
- US stock futures steady after tech slump; investors focus on Middle East tensions
- Lowe's Cos. (LOW) Tops Q2 EPS by 17c, Misses on Revenue; Offers Fy27 Guidance
- Deutsche Bank calls Treasury buyback doubling similar to ’operation twist’
Catalent (CTLT) PT Raised to $137 at RBC Capital, 'COVID-Related Programs Continue to Drive FY21 Outlook Higher'
February 2, 2021 4:20 PM ESTRBC Capital analyst Sean Dodge raised the price target on Catalent (NYSE: CTLT) to $137.00 (from $125.00) while maintaining a Outperform rating.
The analyst comments "F2Q21 results were ahead of consensus on another strong quarter of organic revenue growth (65% YoY) and EBITDA margin expansion... More
Catalent (CTLT) Tops Q2 EPS by 8c, Revenues Beat; Raises FY21 Revenue Guidance Above Consensus
February 2, 2021 7:17 AM ESTCatalent (NYSE: CTLT) reported Q2 EPS of $0.63, $0.08 better than the analyst estimate of $0.55. Revenue for the quarter came in at $910.8 million versus the consensus estimate of $894.58 million.
Q2'21 net revenue of $910.8 million increased 26% as-reported, or 24% in constant currency, compared to Q2'20. Organic, constant currency net revenue grew 17%, compared to Q2'20.Q2'21 net earnings of $88.4 million increased 94%, or 88% in constant currency, compared to Q2'20.Q2'21 Adjusted EBITDA of $223.5 million increased 31% as-reported, or 28% in constant currency, compared to Q2'20.Q2'21 Biologics segment net... More